Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

NCT04954599 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: CP-506
DRUG: Carboplatin
DRUG: Immune checkpoint inhibitor

Sponsor

Maastricht University Medical Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]